Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
University of Oxford
AstraZeneca
University of Illinois at Chicago
Maia Biotechnology
Bristol-Myers Squibb
Intergroupe Francophone de Cancerologie Thoracique
Mario Negri Institute for Pharmacological Research
Gustave Roussy, Cancer Campus, Grand Paris
The Cleveland Clinic
City of Hope Medical Center
EpicentRx, Inc.
National Cancer Institute (NCI)
Jazz Pharmaceuticals
University of Rochester
Hoffmann-La Roche
Qilu Pharmaceutical Co., Ltd.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
AstraZeneca
Shanghai Chest Hospital
Spanish Lung Cancer Group
University of Nebraska
AIO-Studien-gGmbH
Assistance Publique Hopitaux De Marseille
Second Affiliated Hospital of Soochow University
Helix BioPharma Corporation
Odense University Hospital
University Hospital, Brest
Bristol-Myers Squibb
Wales Cancer Trials Unit
Betta Pharmaceuticals Co., Ltd.
Vejle Hospital
Shanghai Chest Hospital
Bayer
CTI BioPharma
Canadian Cancer Trials Group
Guangdong Association of Clinical Trials
Hunan Province Tumor Hospital
Heat Biologics
Shanghai University of Traditional Chinese Medicine
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Shenzhen People's Hospital
Memorial Sloan Kettering Cancer Center
Western Regional Medical Center
Medical University of South Carolina
University Hospital, Limoges
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
GlaxoSmithKline
H. Lee Moffitt Cancer Center and Research Institute
Merck KGaA, Darmstadt, Germany